New Horizons in Cancer Treatment: A Closer Look at Novel PI3Kα Inhibitors.
Robert B KargboPublished in: ACS medicinal chemistry letters (2023)
Phosphoinositide 3-kinase (PI3K), a lipid messenger in cellular biology, regulates numerous cellular responses, including cell survival and migration. Abnormal activation of PI3K has been identified in many human tumors, implicating it as a pivotal point in cancer research. PI3K inhibitors have shown promise in controlling tumor progression and chemotherapy resistance. However, challenges like cutaneous adverse effects require further research. The PI3K signaling pathway's role in cellular processes, such as aging and Alzheimer's disease progression, also signifies its importance in drug development for aging-related diseases. Future research promises innovative therapeutic strategies targeting PI3K in managing cancer, aging, and neurodegenerative diseases. This Patent Highlight showcases compounds and compositions that may enlarge the PI3K inhibitory therapeutic window-effectively inhibiting the target in cancer cells while reducing toxicity in patients.
Keyphrases
- signaling pathway
- papillary thyroid
- end stage renal disease
- squamous cell
- endothelial cells
- chronic kidney disease
- newly diagnosed
- ejection fraction
- epithelial mesenchymal transition
- lymph node metastasis
- prognostic factors
- oxidative stress
- poor prognosis
- pi k akt
- squamous cell carcinoma
- drug delivery
- locally advanced
- radiation therapy
- young adults
- current status
- machine learning
- induced apoptosis
- artificial intelligence
- tyrosine kinase
- long non coding rna